Oncology Beyond the Obvious Conference | 15th May 2022 | Lung Cancer

0 Views

07/07/23

Papers
1) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2) First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
3) Gefitinib Versus Gefitinib Plus Pemetrexed and Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
4) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Moderator - Dr Ullas Batra